Home LiteratureArticle Details
PMID: 21364029 Published · ppublish English Journal Article Multicenter Study Research Support, N.I.H., Extramural

Body size, physical activity, and risk of triple-negative and estrogen receptor-positive breast cancer.

Phipps AI, Chlebowski RT, Prentice R, McTiernan A, Stefanick ML, Wactawski-Wende J, Kuller LH, Adams-Campbell LL, Lane D, Vitolins M, Kabat GC, Rohan TE, Li CI

Abstract

Triple-negative breast cancer, characterized by a lack of hormone receptor and HER2 expression, is associated with a particularly poor prognosis. Focusing on potentially modifiable breast cancer risk factors, we examined the relationship between body size, physical activity, and triple-negative disease risk. Using data from 155,723 women enrolled in the Women's Health Initiative (median follow-up, 7.9 years), we assessed associations between baseline body mass index (BMI), BMI in earlier adulthood, waist and hip circumference, waist-hip ratio, recreational physical activity, and risk of triple-negative (n=307) and estrogen receptor-positive (ER+, n=2,610) breast cancers. Women in the highest versus lowest BMI quartile had 1.35-fold (95% CI, 0.92-1.99) and 1.39-fold (95% CI, 1.22-1.58) increased risks of triple-negative and ER+ breast cancers, respectively. Waist and hip circumferences were positively associated with risk of ER+ breast cancer (Ptrend=0.01 for both measures) but were not associated with triple-negative breast cancer. Compared with women who reported no recreational physical activity, women in the highest activity tertile had similarly lower risks of triple-negative and ER+ breast cancers (HR=0.77; 95% CI, 0.51-1.13; and HR=0.85; 95% CI, 0.74-0.98, respectively). Despite biological and clinical differences, triple-negative and ER+ breast cancers are similarly associated with BMI and recreational physical activity in postmenopausal women. The biological mechanisms underlying these similarities are uncertain and these modest associations require further investigation. If confirmed, these results suggest potential ways postmenopausal women might modify their risk of both ER+ and triple-negative breast cancers.

MeSH Terms
Aged Aged, 80 and over Body Size Breast Neoplasms/epidemiology,metabolism Female Follow-Up Studies Humans Longitudinal Studies Middle Aged Motor Activity Postmenopause Randomized Controlled Trials as Topic Receptor, ErbB-2/metabolism Receptors, Estrogen/metabolism Receptors, Progesterone/metabolism Treatment Outcome United States/epidemiology Waist-Hip Ratio
Chemicals
Receptors, Estrogen Receptors, Progesterone Receptor, ErbB-2
Authors & Affiliations
13 authors, click to expand affiliations / ORCID
Phipps Amanda I
Fred Hutchinson Cancer Research Center, 1100 Fairview Ave. N., M4-B402, P.O. Box 19024, Seattle, WA 98109-1024, USA. aphipps@fhcrc.org
Chlebowski Rowan T
Prentice Ross
McTiernan Anne
Stefanick Marcia L
Wactawski-Wende Jean
Kuller Lewis H
Adams-Campbell Lucile L
Lane Dorothy
Vitolins Mara
Kabat Geoffrey C
Rohan Thomas E
Li Christopher I
References (37)
37 references, click to expand
  1. Physical activity and postmenopausal breast cancer: effect modification by breast cancer subtypes and effective periods in life.
    Cancer Epidemiol Biomarkers Prev. 2008 Dec;17(12):3402-10 PMID: 19029400
  2. Mechanisms linking physical activity with cancer.
    Nat Rev Cancer. 2008 Mar;8(3):205-11 PMID: 18235448
  3. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry.
    Cancer. 2007 May 1;109(9):1721-8 PMID: 17387718
  4. Interactions between body mass index and hormone therapy and postmenopausal breast cancer risk (United States).
    Cancer Causes Control. 2006 Jun;17(5):695-703 PMID: 16633917
  5. Race and triple negative threats to breast cancer survival: a population-based study in Atlanta, GA.
    Breast Cancer Res Treat. 2009 Jan;113(2):357-70 PMID: 18324472
  6. Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance.
    Am J Physiol Endocrinol Metab. 2001 May;280(5):E745-51 PMID: 11287357
  7. Risk factors for triple-negative breast cancer in women under the age of 45 years.
    Cancer Epidemiol Biomarkers Prev. 2009 Apr;18(4):1157-66 PMID: 19336554
  8. The epidemiology of triple-negative breast cancer, including race.
    Cancer Causes Control. 2009 Sep;20(7):1071-82 PMID: 19343511
  9. Differences in risk factors for breast cancer molecular subtypes in a population-based study.
    Cancer Epidemiol Biomarkers Prev. 2007 Mar;16(3):439-43 PMID: 17372238
  10. Adulthood lifetime physical activity and breast cancer.
    Epidemiology. 2008 Mar;19(2):226-36 PMID: 18277160
  11. Body size, physical activity, and breast cancer hormone receptor status: results from two case-control studies.
    Cancer Epidemiol Biomarkers Prev. 2000 Jul;9(7):681-7 PMID: 10919738
  12. Upper abdominal obesity, insulin resistance and breast cancer risk.
    Int J Obes Relat Metab Disord. 2002 Jun;26(6):747-53 PMID: 12037643
  13. Design of the Women's Health Initiative clinical trial and observational study. The Women's Health Initiative Study Group.
    Control Clin Trials. 1998 Feb;19(1):61-109 PMID: 9492970
  14. Epidemiology of basal-like breast cancer.
    Breast Cancer Res Treat. 2008 May;109(1):123-39 PMID: 17578664
  15. The Women's Health Initiative recruitment methods and results.
    Ann Epidemiol. 2003 Oct;13(9 Suppl):S18-77 PMID: 14575939
  16. Compendium of physical activities: classification of energy costs of human physical activities.
    Med Sci Sports Exerc. 1993 Jan;25(1):71-80 PMID: 8292105
  17. Physical activity and breast cancer: a systematic review.
    Epidemiology. 2007 Jan;18(1):137-57 PMID: 17130685
  18. Adult weight gain and histopathologic characteristics of breast cancer among postmenopausal women.
    Cancer. 2006 Jul 1;107(1):12-21 PMID: 16718671
  19. Risk factors for breast cancer according to estrogen and progesterone receptor status.
    J Natl Cancer Inst. 2004 Feb 4;96(3):218-28 PMID: 14759989
  20. Circulating levels of sex hormones and their relation to risk factors for breast cancer: a cross-sectional study in 1092 pre- and postmenopausal women (United Kingdom).
    Cancer Causes Control. 2001 Jan;12(1):47-59 PMID: 11227925
  21. Recreational physical activity and the risk of breast cancer in postmenopausal women: the Women's Health Initiative Cohort Study.
    JAMA. 2003 Sep 10;290(10):1331-6 PMID: 12966124
  22. Body mass index, serum sex hormones, and breast cancer risk in postmenopausal women.
    J Natl Cancer Inst. 2003 Aug 20;95(16):1218-26 PMID: 12928347
  23. Usual physical activity and endogenous sex hormones in postmenopausal women: the European prospective investigation into cancer-norfolk population study.
    Cancer Epidemiol Biomarkers Prev. 2007 May;16(5):900-5 PMID: 17507613
  24. Body weight and incidence of breast cancer defined by estrogen and progesterone receptor status--a meta-analysis.
    Int J Cancer. 2009 Feb 1;124(3):698-712 PMID: 18988226
  25. Body weight and postmenopausal breast cancer risk defined by estrogen and progesterone receptor status among Swedish women: A prospective cohort study.
    Int J Cancer. 2006 Oct 1;119(7):1683-9 PMID: 16646051
  26. Adult weight gain in relation to breast cancer risk by estrogen and progesterone receptor status: a meta-analysis.
    Breast Cancer Res Treat. 2010 Oct;123(3):641-9 PMID: 20711809
  27. Recreational physical activity and risk of postmenopausal breast cancer based on hormone receptor status.
    Arch Intern Med. 2006 Dec 11-25;166(22):2478-83 PMID: 17159013
  28. Dual effects of weight and weight gain on breast cancer risk.
    JAMA. 1997 Nov 5;278(17):1407-11 PMID: 9355998
  29. Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults--The Evidence Report. National Institutes of Health.
    Obes Res. 1998 Sep;6 Suppl 2:51S-209S PMID: 9813653
  30. Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer.
    J Natl Cancer Inst. 2003 Oct 1;95(19):1482-5 PMID: 14519755
  31. Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer.
    J Clin Oncol. 2008 Sep 10;26(26):4282-8 PMID: 18779615
  32. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study.
    JAMA. 2006 Jun 7;295(21):2492-502 PMID: 16757721
  33. Relation of BMI and physical activity to sex hormones in postmenopausal women.
    Obesity (Silver Spring). 2006 Sep;14(9):1662-77 PMID: 17030978
  34. Body size and risk of luminal, HER2-overexpressing, and triple-negative breast cancer in postmenopausal women.
    Cancer Epidemiol Biomarkers Prev. 2008 Aug;17(8):2078-86 PMID: 18664548
  35. Breast cancer subtypes based on ER/PR and Her2 expression: comparison of clinicopathologic features and survival.
    Clin Med Res. 2009 Jun;7(1-2):4-13 PMID: 19574486
  36. Association of physical activity with hormone receptor status: the Shanghai Breast Cancer Study.
    Cancer Epidemiol Biomarkers Prev. 2006 Jun;15(6):1170-8 PMID: 16775177
  37. Anthropometry and breast cancer. Body size--a moving target.
    Cancer. 1994 Aug 1;74(3 Suppl):1090-100 PMID: 8039144
Article Info
Journal
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
Abbr.
Cancer Epidemiol Biomarkers Prev
ISSN
1538-7755
Published
2011-03-00
Epub
2011-00-01
Pages
454-63
Language
English
Region
United States
NLM ID
9200608
PMCID
PMC3064558
Subset
IM
Grants
PHS HHS · 32105-6 · United States
WHI NIH HHS · N01 WH032105 · United States
PHS HHS · 32100-2 · United States
PHS HHS · 24152 · United States
PHS HHS · 42129-32 · United States
NCI NIH HHS · T32 CA009168 · United States
PHS HHS · 32118-32119 · United States
PHS HHS · 32122 · United States
WHI NIH HHS · N01 WH044221 · United States
WHI NIH HHS · N01 WH32115 · United States
NCI NIH HHS · T32 CA09168 · United States
NCI NIH HHS · R25 CA094880-10 · United States
WHI NIH HHS · N01 WH042107 · United States
PHS HHS · 42107-26 · United States
PHS HHS · 32115 · United States
WHI NIH HHS · N01 WH032100 · United States
WHI NIH HHS · N01 WH032111 · United States
WHI NIH HHS · N01 WH032122 · United States
WHI NIH HHS · N01 WH032118 · United States
NCI NIH HHS · R25 CA094880 · United States
NCI NIH HHS · R25-CA-94880 · United States
PHS HHS · 32108-9 · United States
WHI NIH HHS · N01 WH022110-024 · United States
NCI NIH HHS · T32 CA009168-30 · United States
WHI NIH HHS · N01 WH032108 · United States
PHS HHS · 44221 · United States
PHS HHS · 32111-13 · United States
WHI NIH HHS · N01 WH032119 · United States
WHI NIH HHS · N01 WH024152 · United States
WHI NIH HHS · N01WH22110 · United States
WHI NIH HHS · N01 WH042129 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com